Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib Pharmacodynamics in NHL and Solid Tumors
NCT02155582Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of copanlisib in non-Hodgkin lymphoma (NHL) and solid tumor (2 arms), sponsored by Bayer. Primary endpoints: Maximum change from baseline in expression of pathway inhibition (pAKT) in surrogate tissue at 2 years and Maximum change from baseline in plasma glucose at Day 22. Started Aug 2014; status: completed.
02
Drugs
copanlisib
03
Conditions
non-Hodgkin lymphoma (NHL)solid tumor
Beyond the preview
Go deeper on NCT02155582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02155582.